Wednesday, May 25, 2016
A full service retail broker-dealer, New York City-based Aegis Capital Corp. offers a host of services to diverse institutional and retail clients. In March 2016, Aegis Capital Corp. took a lead management role in a firm commitment underwritten public offering for CombiMatrix Corporation.
A molecular diagnostics enterprise, CombiMatrix offers pre-implantation genetic screening and DNA-based testing focused on identifying postnatal and prenatal developmental disorders. Committed to the highest-quality diagnostics, the firm has developed an advanced cytogenomic approach that can identify abnormalities beyond those that conventional approaches can discern. Uses of the technologies extend to pediatric genetics and analysis of miscarriages within a pattern of recurrent pregnancy loss.
With 8,000 Series F units of convertible preferred stock made available to the public, the Aegis-enabled offering translates to $8 million in gross proceeds prior to the deduction of expenses, commissions, and underwriting discounts. The deal also involved the participation of Ladenburg Thalmann Financial Services, Inc., a subsidiary of Ladenburg Thalmann & Co. Inc., as the bookrunning manager.